Today: 10 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone shares fell 0.4% to 98.3 pence by 0932 GMT in London, after a 2.6% drop Tuesday, despite another buyback announcement. The company repurchased over 5.2 million shares on Jan. 13, adding to its treasury stock. Investors are awaiting Vodafone’s trading update on Feb. 5 for further direction. UBS maintained its “sell” rating but raised the target price to 82 pence.
14 January 2026
··
South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up

South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up

South Korea’s Financial Services Commission delayed a decision on preliminary licenses for new over-the-counter marketplaces for tokenized securities at its Jan. 14 meeting. Lucentblock accused rival Nextrade of misusing confidential information, which Nextrade denied. The regulator was expected to pick up to two operators from three contenders. The delay leaves the selection unresolved and intensifies pressure on Lucentblock.
14 January 2026
··
Imperial Brands stock holds steady after fresh buyback disclosure; AGM and dividend dates loom

Imperial Brands stock holds steady after fresh buyback disclosure; AGM and dividend dates loom

Imperial Brands PLC repurchased 291,666 shares on Jan. 13 at an average price of 3,012.98 pence, canceling them to reduce shares outstanding to 793,362,213. Shares traded near 3,009 pence early Wednesday, little changed after the buyback news. The company’s annual meeting is set for Jan. 28, with a final dividend payment scheduled for March 31, pending approval.
14 January 2026
··
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
Rio Tinto plc stock edges up as Glencore deal talk deepens with bank advisers lined up

Rio Tinto plc stock edges up as Glencore deal talk deepens with bank advisers lined up

Rio Tinto shares rose 0.3% to 6,231 pence after reports it hired JPMorgan, Evercore, and Macquarie to advise on a possible Glencore takeover. The potential deal could create a $200 billion mining group. Rio has until Feb. 5 to make a formal offer or withdraw, and said there’s no guarantee a bid will happen. BHP is not planning a rival bid, according to sources.
14 January 2026
···
Reckitt Benckiser stock dips after RBC downgrade as a big cash-return vote closes in

Reckitt Benckiser stock dips after RBC downgrade as a big cash-return vote closes in

Reckitt shares fell nearly 0.8% in early London trading after RBC Capital Markets downgraded the stock to “sector perform” and cut its price target to 6,200 pence. The move comes ahead of a shareholder vote on a 235 pence special dividend and share consolidation set for January 27. Reckitt recently completed the sale of its Essential Home business and repurchased 48,340 shares on January 13. Full-year results are due March 5.
14 January 2026
·
1 … 233 234 235 236 237 … 584
Go toTop